Below are featured speakers for the 2019 Constellation Forum. Check back soon for new speaker additions.

Portrait of Lidia Fonseca

Lidia Fonseca

Executive Vice President, Chief Digital and Technology Officer

Portrait of Adam Koppel

Adam Koppel

Managing Director, Life Sciences
Bain Capital

Portrait of Geoffrey Ling

Geoffrey Ling

Chief Executive Officer
Ling and Associates

Portrait of Tom Lee

Tom Lee

Chief Medical Officer
Press Ganey

Portrait of Justin Sanchez

Justin Sanchez

Life Sciences Research Technical Fellow

Portrait of Trevor Hawkins

Trevor Hawkins

President & CEO

Trevor Hawkins’ 25+ year career in healthcare has included business, academic innovation and entrepreneurship. He is a visiting Professor at NYU and serves on several boards focusing on new technology and innovative solutions. Dr. Hawkins was previously Director of the Human Genome Project for the DOE, and held senior executive roles at Siemens Healthcare, Philips, GE Healthcare and Amersham. He was also previously Chairman & CEO of ProGenTech, a privately held company based in Shanghai & San Francisco, and a founder of the Beijing Genome Institute, of which he remains an Honorary Professor and Director. Dr. Hawkins invented SPRI – Solid Phase Reversible Immobilization – the magnetic bead nucleic acid isolation method used as the sample prep method for the Human Genome Project. Dr. Hawkins has published over 50 peer-reviewed articles on automation, genomics, human diseases and the human genome project.

Portrait of Dean Kamen

Dean Kamen

DEKA Research and Development

Dean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined—his own passion for technology and its practical uses has driven his personal determination to spread the word about technology’s virtues and by so doing to change the culture of the United States.

As an inventor, he holds more than 440 U.S. and foreign patents, many of them for innovative medical devices that have expanded the frontiers of health care worldwide. While still a college undergraduate, he invented the first wearable infusion pump, which rapidly gained acceptance from such diverse medical specialties as oncology, neonatology, and endocrinology. In 1976, he founded his first medical device company, AutoSyringe, Inc., to manufacture and market the pumps. Then, working with leading diabetes researchers, Dean pioneered the design and adoption of the first portable insulin pump. It was quickly demonstrated that using a pump could much more effectively control patients’ blood glucose levels. . At age 30, he sold AutoSyringe to Baxter Healthcare Corporation.
Following the sale of Auto
Syringe, Inc., he founded DEKA Research & Development Corporation to develop internally generated inventions as well as to provide research and development for major corporate clients. Kamen led DEKA’s development of the HomeChoiceTM peritoneal dialysis system for Baxter International Inc. The HomeChoiceTM system allows patients to be dialyzed in the privacy and comfort of their home and quickly became the worldwide market leader. Kamen also led the development of technology to improve slide preparation for the CYTYC (now Hologic Inc.) ThinPrep® Pap Test. Kamen-led DEKA teams have also developed critical components of the UVARTM XTSTM System, an extracorporeal photophereisis device marketed by Therakos, a unit of Johnson & Johnson, for treatment of T-Cell lymphoma. An advanced prosthetic arm in development for DARPA should advance the quality of life for returning injured soldiers. Other notable developments include the HydroflexTM surgical irrigation pump for C.R. Bard, the CrownTM stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOTTM mobility device, and the Segway® Human Transporter.

Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was elected a member of the National Academy of Engineering in 1997. He was awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, as well as many other national and international engineering organizations.

In 2010, Dean hosted the Planet Green television series Dean of Invention.

In addition to DEKA, one of Dean’s proudest accomplishments is founding FIRST® (For Inspiration and Recognition of Science and Technology), an organization dedicated to motivating the next generation to understand, use and enjoy science and technology. Founded in 1989, this year FIRST® will serve more than 1,000,000 young people, ages 6 to 18, in more than 86 countries around the globe. Last year, high-school-aged participants were eligible to apply for more than $50 million in scholarships from over 200 leading colleges, universities, and corporations.

Portrait of Sat Pannu

Sat Pannu

Head of Advance Technology

Dr. Satinderpall (Sat) Pannu is the Director for the Center for Bioengineering and most recently the Section Leader for the Center for Micro- and Nano-Technology at Lawrence Livermore National Laboratory where he managed a group of over 130 scientists and engineers dedicated to the research of bioengineering and nanotechnology. As Director of the Center for Bioengineering, Dr. Pannu leads a research team developing biomedical devices with significant interests in developing implantable neural interfaces for humans. His team, in conjunction with the Department of Energy’s Artificial Retina program, developed the world’s first the retinal prosthesis which has been implanted in over fifty patients and approved for sale in Europe and recently obtained FDA approval in the US. Dr. Pannu and his team are pushing the boundaries of implantable neural interface technologies for chronic recording and stimulating from the central and peripheral nervous systems. These technologies include biocompatible polymers, electrode materials, hermetic packaging, dielectric coatings, and wireless electronics for neural prosthetic systems.

Portrait of Wolfgang Baiker

Wolfgang Baiker

CEO and US Country Managing Director
Boehringer Ingelheim

Dr. Wolfgang Baiker serves as President & CEO of Boehringer Ingelheim Pharmaceuticals, Inc. since March 01, 2018. He joined Boehringer Ingelheim in 1989 as Section Head for Clinical Development in Biberach, Germany. Since then, Dr. Baiker has served in a number of senior leadership roles across several critical business functions, including Head of International Project Management, Head of Global Development, Member of the Board of Managing Directors (BMD) responsible for Corporate Board Division Biopharmaceuticals and Operations and currently, as a key member of the worldwide Human Pharma Executive Committee. He serves as a Venture Partner of Wellington Ventures. Dr. Baiker has been a Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG and Boehringer Ingelheim GmbH since July 1, 2013. He works as the biopharmaceuticals and operations division, where he advises a fledgling company that was created in April 2014 as a spin-off from German research network the Life Science Inkubator. He served as a Senior Vice President of Development at Boehringer Ingelheim GmbH. He has been a Member of Advisory Board of NEUWAY Pharma GmbH since July 2014. Dr. Baiker also has significant experience working in the U.S. gained during a seven-year assignment in Ridgefield, CT where he held several different leadership roles within Clinical Development and Clinical Research. Dr. Baiker completed his medical studies and doctorate at the Universities of Bochum, Berlin, Ulm, Munich and Sheffield and received his MBA from Pace University in New York.

Portrait of Michael Dowling

Michael Dowling

President & CEO
Northwell Health

Michael J. Dowling is president and chief executive officer of Northwell Health, which delivers world-class clinical care throughout the New York metropolitan area, pioneering research at the Feinstein Institute for Medical Research and a visionary approach to medical education highlighted by the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the School of Graduate Nursing and Physician Assistant Studies.

Northwell Health is the largest integrated health care system in New York State with a total workforce of more than 66,000 employees — the state’s largest private employer. With 23 hospitals, 6,675 hospital and long-term care beds, more than 665 outpatient physician practices and a full complement of long-term care services, Northwell is one of the nation’s largest health systems, with $11 billion in annual revenue.

Prior to becoming president and CEO in 2002, Mr. Dowling was the health system’s executive vice president and chief operating officer. Before joining Northwell Health in 1995, he was a senior vice president at Empire Blue Cross/Blue Shield. Mr. Dowling served in New York State government for 12 years, including seven years as state director of Health, Education and Human Services and deputy secretary to the governor. He was also commissioner of the New York State Department of Social Services.

Before his public service career, Mr. Dowling was a professor of social policy and assistant dean at the Fordham University Graduate School of Social Services, and director of the Fordham campus in Westchester County.

Mr. Dowling has been honored with many awards over the years. They include: his selection as the Grand Marshal of the 2017 St. Patrick’s Day Parade in New York City; induction into the Irish America Hall of Fame; the 2012 B’nai B’rith National Healthcare Award, the Ellis Island Medal of Honor, the 2011 Gail L. Warden Leadership Excellence Award from the National Center for Healthcare Leadership, the 2011 CEO Information Technology Award from Modern Healthcare magazine and the Healthcare Information and Management Systems Society, the National Human Relations Award from the American Jewish Committee, the Distinguished Public Service Award from the State University of New York’s Nelson A. Rockefeller College of Public Affairs and Policy, an Outstanding Public Service Award from the Mental Health Association of New York State, an Outstanding Public Service Award from the Mental Health Association of Nassau County, the Alfred E. Smith Award from the American Society for Public Administration, and the Gold Medal from the American Irish Historical Society. For 11 consecutive years, Modern Healthcare has ranked Mr. Dowling on its annual list of the “100 Most Powerful People in Healthcare.” In March 2016, Mr. Dowling was also listed No. 1 on Long Island Press’ 2015 “Power List” recognizing the 50 most-influential Long Islanders.

Mr. Dowling is chair of the Healthcare Institute and the Institute for Healthcare Improvement (IHI). He is a member of the Institute of Medicine of the National Academies of Sciences and the North American Board of the Smurfit School of Business at University College, Dublin, Ireland. He also serves as a board member of the Long Island Association. He is past chair and a current board member of the National Center for Healthcare Leadership (NCHL), the Greater New York Hospital Association (GNYHA), the Healthcare Association of New York State (HANYS) and the League of Voluntary Hospitals of New York. Mr. Dowling was an instructor at the Center for Continuing Professional Education at the Harvard School of Public Health.

Mr. Dowling grew up in Limerick, Ireland. He earned his undergraduate degree from University College Cork (UCC), Ireland, and his master’s degree from Fordham University. He also has honorary doctorates from Queen’s University Belfast, University College Dublin, Hofstra University, Dowling College and Fordham University

Portrait of Bruce Broussard

Bruce Broussard

President and Chief Executive Officer

Bruce D. Broussard, President and CEO, joined Humana in 2011. Under his leadership, Humana has created an integrated care delivery model centered on improving health outcomes, driving lower costs, enhancing quality, and providing a simple and personalized member experience. With its holistic approach, Humana is dedicated to improving the health of the communities it serves by making it easy for people to achieve their best health.

Bruce brings to Humana a wide range of executive leadership experience in publicly traded and private organizations within a variety of healthcare sectors, including oncology, pharmaceuticals, assisted living/senior housing, home care, physician practice management, surgical centers and dental networks.

Prior to joining Humana, Bruce was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Bruce served in a number of senior executive roles, including Chief Financial Officer, President, Chief Executive Officer and Chairman of the Board.

Bruce plays a leadership role in key business advocacy organizations such as The Business Council and the American Heart Association CEO Roundtable. He is also a member of the Board of Directors of KeyCorp and the World Economic Forum Health Governors Board.

Portrait of Geoff Martha

Geoff Martha

Executive Vice President

Geoff Martha is Executive Vice President and President of Medtronic’s Restorative Therapies Group (RTG) – one of four Medtronic business groups – with over $8B in annual revenue and approximately 14,000 employees worldwide. He also serves as a member of the company’s Executive Committee.

Geoff has global responsibility for RTG’s four divisions, which include Brain Therapies, Pain Therapies, Specialty Therapies and Spine. He provides overall strategic direction and operational management, as well as leads the integration of the group’s activities within the overall strategy of Medtronic. Previously, Geoff was Senior Vice President of Strategy and Business Development for Medtronic and had responsibility for leading the development of Medtronic’s global strategic plan, business development and acquisition-integration.

As head of Strategy and Business Development, Geoff led the acquisition of Covidien, a $10 billion global manufacturer of surgical products and supplies. The acquisition of Covidien was the largest medical technology acquisition in the history of the industry. In July 2014, he was named Chief Integration Officer to lead the integration of Covidien into Medtronic.
Geoff serves as the Executive Sponsor of the African-Descent Network – an internal national resource group that focuses on recruitment, engagement, retention and development for Medtronic employees of African descent. An ardent supporter of Medtronic-sponsored philanthropic initiatives, Geoff also is a member of the Medtronic Foundation Board of Directors and serves as Medtronic’s Executive Sponsor to FIRST Robotics.

Prior to joining Medtronic, Geoff served as Managing Director of Business Development at GE Healthcare, where he was responsible for global business development, including acquisitions, divestitures, joint ventures and equity investments. In his 19-year career with GE, which included significant time with GE Capital, Geoff held several executive roles in business leadership, corporate development, strategic marketing, and sales management.

Passionate about socio-economic issues, Geoff serves on the boards of two Minneapolis-based nonprofit organizations: Children’s HeartLink and Northside Achievement Zone (NAZ). Children’s HeartLink provides access to care for children around the world with congenital heart defects. NAZ is a community collaborative that works to end generational poverty and build a culture of achievement in North Minneapolis so low-income children of color graduate college and are career-ready.

Geoff received a bachelor’s degree in Finance as a member of the Scholar’s Program from Pennsylvania State University. He graduated in 1992 with highest honors. Geoff was captain of the Penn State men’s hockey team and was later inducted into its Hockey Hall of Fame in 1998. The University awarded him the 2016 Penn State Hockey Distinguished Alumni Award.

Portrait of France Córdova

France Córdova

National Science Foundation

France A. Córdova is an astrophysicist and the 14th director of the National Science Foundation (NSF), the only government agency charged with advancing all fields of scientific discovery, technological innovation, and science, technology, engineering and mathematics (STEM) education. NSF is a $7.5 billion independent federal agency; its programs and initiatives keep the United States at the forefront of science and engineering, empower future generations of scientists and engineers, and foster U.S. prosperity and global leadership.

Córdova is president emerita of Purdue University, and chancellor emerita of the University of California, Riverside, where she was a distinguished professor of physics and astronomy. Córdova was the vice chancellor for research and professor of physics at the University of California, Santa Barbara.

Previously, Córdova served as NASA’s chief scientist. Prior to joining NASA, she was on the faculty of the Pennsylvania State University where she headed the department of astronomy and astrophysics. Córdova was also deputy group leader in the Earth and space sciences division at Los Alamos National Laboratory. She received her Bachelor of Arts degree from Stanford University and her doctorate in physics from the California Institute of Technology.

More recently, Córdova served as chair of the Board of Regents of the Smithsonian Institution and on the board of trustees of Mayo Clinic. She also served as a member of the National Science Board (NSB), where she chaired the Committee on Strategy and Budget. As NSF director, she is an ex officio member of the NSB.

Córdova’s scientific contributions have been in the areas of observational and experimental astrophysics, multi-spectral research on x-ray and gamma ray sources and space-borne instrumentation. She has published more than 150 scientific papers. She has been awarded several honorary doctorates, including ones from Purdue and Duke Universities. She is a recipient of NASA’s highest honor, the Distinguished Service Medal, and was recognized as a Kilby Laureate. The Kilby International Awards recognize extraordinary individuals who have made “significant contributions to society through science, technology, innovation, invention and education.” Córdova was elected to the American Academy of Arts and Sciences and is a National Associate of the National Academies. She is also a fellow of the American Association for the Advancement of Science (AAAS) and the Association for Women in Science (AWIS).
Córdova is married to Christian J. Foster, a science educator, and they have two adult children.

Portrait of Lawrence Tabak

Lawrence Tabak

Principal Deputy Director
National Institutes of Health

Dr. Tabak is the Principal Deputy Director of the National Institutes of Health (NIH) and the Deputy Ethics Counselor of the Agency. He previously served as the Acting Principal Deputy Director of NIH (2009), and prior to that as Director of the National Institute of Dental and Craniofacial Research from 2000-10.

Dr. Tabak has provided leadership for numerous trans-NIH activities, including the NIH Roadmap effort to support team science; the NIH Director’s initiative to enhance peer review; NIH’s American Recovery and Reinvestment Act implementation; the NIH initiative to enhance rigor and reproducibility in research; and the NIH-Wide Strategic Plan. He co-chaired working groups of the Advisory Committee to the Director of NIH on the Diversity of the Biomedical Research Workforce, the Long-Term Intramural Research Program, and, currently is co-chair of both the Next Generation Researcher’s Initiative and High Risk High Reward Research working groups.

Prior to joining NIH, Dr. Tabak was the Senior Associate Dean for Research and Professor of Dentistry and Biochemistry & Biophysics in the School of Medicine and Dentistry at the University of Rochester in New York. A former NIH MERIT recipient, Dr. Tabak’s major research focus has been on the structure, biosynthesis and function of glycoproteins. He continues work in this area, maintaining an active research laboratory within the NIH intramural program in addition to his administrative duties. He is an elected member the National Academy of Medicine of the National Academies.

Portrait of Vikram Bajaj

Vikram Bajaj

Managing Director
Foresite Capital Management

Vik is a Managing Director at Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare.
Prior to joining Foresite Capital, Vik was the Chief Scientific Officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as Chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as Associate Professor (consulting) at the Stanford School of Medicine, and as an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology.

Vik’s research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development.

He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy’s LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.

Portrait of Emmanuel Fombu

Emmanuel Fombu

Global Commercial Strategy and Digital Innovation
Johnson & Johnson

Emmanuel Fombu, MD, MBA, is an Ivy League educated physician, author, speaker and healthcare executive turned Silicon Valley entrepreneur. He is a medical futurist, an advocate for value-based healthcare and the 2017 winner of the prestigious New York City Health Business Leaders Boldest Digital Health Influencer Award.

As a medical futurist, Dr. Fombu champions the potential for the internet of things, AI and machine learning to revolutionize the healthcare industry. He’s passionate about m-health, personalized medicine, genomics, nanotechnology, big data, artificial intelligence, machine learning, the internet of things and digital medicine. He serves as an external advisory board member on the Massachusetts Institute of Technology’s MIT.nano project.

Dr. Fombu trained at Emory-Crawford Long Hospital and holds an MBA from Cornell University’s Johnson School of Business and a certification on artificial intelligence from MIT’s Computer Science and Artificial Intelligence Lab. He’s taught allied health students, founded a health and education focused non-profit organization and advocates for patients with rare and chronic diseases. Dr Fombu works extensively with venture capitalists and start-ups in digital health and biotech.

In addition to The Future of Healthcare: Humans and Machines Partnering for Better Outcomes, Dr. Fombu has published multiple scientific papers in world renowned, peer reviewed scientific journals. He lives in New York City.

Portrait of Kathleen Gondek

Kathleen Gondek

Global Head of Outcomes Research and Epidemiology
Takeda Pharmaceuticals

Kathleen Gondek, PhD, is currently the Global Head of Outcomes Research and Epidemiology at Takeda.

Kathleen spent the last four years at Shire as Global Head of Outcomes Research and Epidemiology. Prior to joining Shire she was Vice President, US Medical Science Liaisons and Medical Affairs Operations at Bayer HealthCare pharmaceuticals. Prior to this role Kathleen held a number of positions, of increasing responsibility, within the Health Economics and Outcomes Research (HEOR) function at Bayer that span a 15-year career with the organization. These include Director HEOR US, Head of Global HEOR for Life Cycle Management, Anti-infectives, Men’s Health and Oncology and Vice President, Global Health Economics and Outcomes Research, Specialty Medicine. Prior to joining Bayer, Kathleen worked at Boehringer Ingelheim Pharmaceuticals. Kathleen is a coauthor on 45 peer reviewed publications and over 100 presentations.

Kathleen holds a Bachelor’s Degree in Pharmacy from the State University of New York at Buffalo and a Ph.D. in Pharmacy Practice and Administrative Science from the University of Maryland at Baltimore. While at Bayer, Kathleen was a lecturer at Yale University in the School of Public Health.

Portrait of Jonathan Bush

Jonathan Bush

Former CEO

Jonathan Bush is Former Chief Executive Officer, President, and Chairman of the Board of Directors of athenahealth, Inc. He co-founded the Company in 1997 and took it public in 2007 in the most successful initial public offering that year. Today, athenahealth remains one of the health care information technology industry’s fastest growing companies.

Bush’s views on health care and the idea for athenahealth were born from failures with the earliest iteration of its business model. Bush co-founded and operated a birthing clinic with the idea of franchising a network of clinics that viewed pregnancy holistically. Bush would soon realize that his birthing clinic vision was challenged by his business’ own inability to track outstanding claims to insurers and get paid in a reasonable timeframe. This challenge would shape the formation of athenahealth as it is known today. As a result of the challenges with the clinics, Bush and his partners set about designing a solution to address the costly administrative inefficiencies that plagued their business. In doing so, they came to realize their circumstance was more typical than unique and that the solution they architected had great application and utility for the broader health delivery system. Given his vision for an information infrastructure that makes health care work as it should, Bush is focused on creating a true, win-win marketplace that enables a broad and efficient exchange of health information. Bush’s passion for health care extends beyond the evolution of athenahealth.

Previously, Bush served on the frontlines of health care as an EMT for the City of New Orleans, was trained as a medic in the U.S. Army, and worked as a management consultant in the health care practice of Booz Allen & Hamilton. Bush is an active commentator on all things health care and a believer in free market economics. A well-recognized innovator and disruptor, Bush’s vision has been chronicled in the Wall Street Journal Fast Company, and National Public Radio. He has appeared on stage at TedMed, the Forbes Healthcare Summit, and Ignition by Business Insider, among many others. Bush obtained a Bachelor of Arts in the College of Social Studies from Wesleyan University and an M.B.A. from Harvard Business School. He is the author of Where Does it Hurt?: An Entrepreneur’s Guide to Fixing Health Care. He currently serves on the Harvard Medical School Board of Fellows.

Portrait of Christine Guo

Christine Guo

Vice President
Wells Fargo Strategic Capital

Christine Guo is an early stage healthcare investor and founding member of the Wells Fargo Strategic Capital healthcare team. Wells Fargo Strategic Capital is the venture capital and growth equity arm of Wells Fargo, the world’ s second-largest bank by market capitalization. Prior to joining Wells Fargo, Christine was previously at Collective Health, New Enterprise Associates, and Goldman Sachs. She graduated from Harvard Business School and the University of Pennsylvania.

Portrait of Tejal Gandhi

Tejal Gandhi

Chief Clinical and Safety Officer
Institute for Healthcare Improvement

Tejal K. Gandhi, MD, MPH, CPPS, is Chief Clinical and Safety Officer at the Institute for Healthcare Improvement and President of the IHI/NPSF Lucian Leape Institute.

She is a prominent advocate for patient safety at the regional, national and international levels, driving educational and professional certification efforts, and helping to create and spread innovative new safety ideas. Dr. Gandhi was formerly the Executive Director of Quality and Safety at Brigham and Women’s Hospital, and Chief Quality and Safety Officer at Partners Healthcare. In these roles, she led the efforts to standardize and implement patient safety best practices across hospital and health systems.

Throughout her career, Dr. Gandhi has been committed to educating other clinicians on the topic of patient safety. She is regularly invited to speak on this issue, has mentored physicians in post-doctoral study, and frequently served on regional and national committees and boards. She was included in Modern Healthcare’s 100 Most Influential People in Healthcare 2014-2015; Top 25 Women in Healthcare 2015; and 50 Most Influential Physician Executives and Leaders 2016.

Dr. Gandhi’s research interests focus on patient safety and reducing error using information systems. In 2009, she received the John M. Eisenberg Patient Safety and Quality Award for her contributions to understanding the epidemiology and possible prevention strategies for medical errors in the outpatient setting.

Dr. Gandhi is an internist and Associate Professor of Medicine at Harvard Medical School, and she is a Certified Professional in Patient Safety. She received her MD and MPH from Harvard Medical School and the Harvard School of Public Health, and trained at Duke University Medical Center. Her undergraduate training at Cornell University was in biochemistry.

Portrait of Sendhil Mullainathan

Sendhil Mullainathan

Professor of Computation and Behavioral Science
University of Chicago

Sendhil Mullainathan is the Roman Family University Professor of Computation and Behavioral Science at Chicago Booth. His current research uses machine learning to understand complex problems in human behavior, social policy, and especially medicine, where computational techniques have the potential to uncover biomedical insights from large-scale health data. He currently teaches a course on Artificial Intelligence.

In past work he has combined insights from economics and behavioral science with causal inference tools—lab, field, and natural experiments—to study social problems such as discrimination and poverty. Papers include: the impact of poverty on mental bandwidth; how algorithms can improve on judicial decision-making; whether CEO pay is excessive; using fictitious resumes to measure discrimination; showing that higher cigarette taxes makes smokers happier; and modeling how competition affects media bias.

Mullainathan enjoys writing. He recently co-authored Scarcity: Why Having too Little Means so Much and writes regularly for the New York Times. Additionally, his research has appeared in a variety of publications including the Quarterly Journal of Economics, Science, American Economic Review, Psychological Science, the British Medical Journal, and Management Science.
Mullainathan helped co-found a non-profit to apply behavioral science (ideas42), co-founded a center to promote the use of randomized control trials in development (the Abdul Latif Jameel Poverty Action Lab), serves on the board of the MacArthur Foundation, has worked in government in various roles, is affiliated with the NBER and BREAD, and is a member of the American Academy of Arts and Sciences.

Prior to joining Booth, Mullainathan was the Robert C. Waggoner Professor of Economics in the Faculty of Arts and Sciences at Harvard University, where he taught courses about machine learning and big data. He began his academic career at the Massachusetts Institute of Technology.

Mullainathan is a recipient of the MacArthur “Genius Grant,” has been designated a “Young Global Leader” by the World Economic Forum, was labeled a “Top 100 Thinker” by Foreign Policy Magazine, and was named to the “Smart List: 50 people who will change the world” by Wired Magazine (UK). His hobbies include basketball, board games, googling, and fixing up classic espresso machines.

Portrait of Peter Wilderotter

Peter Wilderotter

Christopher and Dana Reeve Foundation

With over three decades of experience working in the nonprofit sector, Peter Wilderotter has leveraged his expertise to expand and advance the mission of several organizations.
Peter was appointed as the President and CEO of the Christopher & Dana Reeve Foundation in 2007 after revamping how the organization approached fundraising. Reporting to the Board of Directors, Peter is responsible for setting the overarching vision for the Reeve Foundation and rallying support for initiatives that speed the delivery of treatments for spinal cord injury.
Before locking arms with the Reeve Foundation, Peter was the Vice President of Development at WNYC Radio, America’s largest public radio station. Previously, Peter held leadership roles at Planned Parenthood Federation of America and the NAACP, and started his career at the American Cancer Society.

Portrait of Lance Becker

Lance Becker

Professor and Chair of Emergency Medicine
Northwell Health

Lance Becker, MD, joined Northwell Health in 2015 as chair of the Department of Emergency Medicine at North Shore University Hospital and Long Island Jewish Medical Center, professor and chair of emergency medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and an investigator at the Feinstein Institute for Medical Research.

A national and international leader in academic emergency medicine, critical care and resuscitation science, Dr. Becker has research interests that are translational and extend across the basic science laboratory into animal models of resuscitation and to human therapies. He has been a leader in the field of resuscitation for more than 25 years, pioneering advances in improving the quality of CPR, AED use, defining the “three-phase” model for cardiac arrest care and therapeutic hypothermia. He has worked closely with the American Heart Association in emphasizing the importance of a “systems of care” approach to improving survival within communities.

Dr. Becker’s cellular studies have helped define reperfusion injury mechanisms, mitochondrial oxidant generation, reactive oxygen and nitrogen species responses to ischemia, apoptotic activation following ischemia, signaling pathways, new cellular cytoprotective strategies and hypothermia protection. He has received numerous honors and awards from organizations such as the American Heart Association, the American College of Emergency Physicians and American Society of Critical Care.

A recipient of prestigious teaching awards, Dr. Becker has mentored many successful researchers. He is a renowned, well-funded researcher who holds many patents for his discoveries. His professional affiliations include membership in the American Heart Association, Society of Academic Emergency Medicine, the US Institute of Medicine, the National Academy of Science, the American College of Emergency Physicians and the American Physiological Society. In addition, he holds many offices in professional and scientific societies, and has organized many national and international scientific meetings. He is an elected member of the Institute of Medicine/National Academy of Medicine.

Before joining Northwell, Dr. Becker was founder and director of the Center for Resuscitation Science at the Hospital of the University of Pennsylvania in Philadelphia, and professor of the Center for Mitochondrial and Epigenomic Medicine at the Children’s Hospital of Philadelphia. He was previously founder and director of the Emergency Resuscitation Center at the University of Chicago and Argonne National Laboratory.

Dr. Becker received his medical degree from the University of Illinois, College of Medicine.

Portrait of Kevin Tracey

Kevin Tracey

President & CEO,
Feinstein Institute for Medical Research
Northwell Health

Kevin J. Tracey, is President and CEO of The Feinstein Institute for Medical Research; Professor of Neurosurgery and Molecular Medicine at the Zucker School of Medicine at Hofstra-Northwell; and Executive Vice President, Research, at Northwell Health, in New York. A leader in the fields of inflammation research and bioelectronic medicine, his contributions to science include discovery and molecular mapping of neural circuits that control immune responses; identifying HMGB1, an abundant component in cell nuclei, as a therapeutic target at the intersection of sterile and infective inflammation; and identifying the therapeutic anti-inflammatory activity of monoclonal anti-TNF antibodies. Professor Tracey received his B.S. (Chemistry, summa cum laude, Phi Beta Kappa) from Boston College in 1979, and his M.D. from Boston University in 1983. He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical, Center, and was a guest investigator at the Rockefeller University, before moving in 1992 to The Feinstein Institute in New York. An inventor with more than 60 United States patents, and author of more than 360 scientific publications, he is also cofounder of the Global Sepsis Alliance, a non-profit organization supporting the efforts of >1 million caregivers in more than 70 countries. His honors and awards include a Doctorate honoris causa from the Karolinska Institute, Stockholm, Sweden and lectureships from Harvard, Yale, Rockefeller University, the NIH, and elsewhere. He has been elected or inducted into the American Society of Clinical Investigation (2001), the American Association of Physicians (2009), the Long Island Technology Hall of Fame (2012), Alpha Omega Alpha (2014), and is a Fellow in the American Association for the Advancement of Science. Professor Tracey is also the author of “Fatal Sequence.”